Menu Back toInstructors

#25: Regulatory Considerations for Drug Development: Current Status and Trend of IND/NDA Practice in China


  • Daniel  Liu, PhD, MSc

    Daniel Liu, PhD, MSc

    • Chief Scientific Officer
    • Beijing Clinical Service Center, China

    20 years in the pharmaceutical industry in the management of global clinical trials. A core expert in the Steering Committee of State Clinical Data Standardization, CDE CFDA; Associate Director of CDM China; Professor at CFDA Inst of Executive Development; Writer- in- chief of "Clinical Trial Methodology of Medicinal Products"; Co-author for books: "GCP: A Q&A Reference Guide", "New Drug Approval Process", "Computerized Systems in Clinical Research: Current Quality and Data Integrity Concept".

  • Earl W. Hulihan, MEd

    Earl W. Hulihan, MEd

    • Professor
    • SUTCM, United States

    Professor Hulihan is Principal with ew hulihan and associates, inc. For over 35+ years, Hulihan has been active in the DIA, in Medicine, as well as providing regulatory consulting, auditing, and training services to the global pharmaceutical community and regulatory authority personnel worldwide.

Contact us

Registration Questions?

Send Email